Multivalent Receptor Coupling Agents for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments using TNF family receptor activating agents are limited by their effectiveness on only a subset of tumors, as they often fail to activate multiple TNF family receptors simultaneously, thereby restricting their therapeutic potential.
Innovation Solution
Development of receptor coupling agents that specifically activate at least two distinct TNF family receptors, enhancing receptor signaling by forming heteromeric receptor complexes, either through antibodies or antigen binding fragments, to induce cell death in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If single TNF family receptor activating agents are used, then the treatment mechanism is simple, but the therapeutic effectiveness is limited to a subset of tumors
Solution Approach 1:
The patent applies multi-functionality by designing receptor coupling agents that can simultaneously activate multiple TNF family receptors (such as TNFR1, TNFR2, Fas, TRAIL-R1, TRAIL-R2, and LT-β-R) through a single agent. This allows the agent to serve multiple therapeutic functions across different tumor types that express various receptor combinations, thereby improving versatility without requiring separate treatments for each receptor type.
Solution Approach 2:
The patent merges multiple receptor activation capabilities into a single coupling agent structure. By combining binding specificities for different TNF family receptors in one agent, the patent creates a unified therapeutic tool that can engage multiple signaling pathways simultaneously, resolving the contradiction between simplicity and effectiveness.
2Reliability
If multiple TNF family receptors are activated simultaneously, then the therapeutic efficacy is enhanced, but the agent complexity increases
Solution Approach 1:
The patent uses antibody or antigen-binding fragment structures as intermediary components that mediate the simultaneous activation of multiple receptors. These intermediary binding moieties are engineered to contain multiple binding specificities, allowing a single agent to bridge multiple receptor types without requiring complex multi-component systems.
Solution Approach 2:
The receptor coupling agents are constructed as composite molecular structures combining different binding specificities (such as bispecific or multispecific antibodies) within a single agent framework. This composite approach allows the integration of multiple receptor-targeting capabilities while maintaining a unified agent structure that can be administered as a single therapeutic product.
3Ease of operation
If conventional TNF activating agents are used, then the treatment approach is straightforward, but liver toxicity occurs
Solution Approach 1:
The patent applies local quality by designing receptor coupling agents with tailored binding specificities that target tumor-expressed receptor combinations while sparing normal liver tissue. By adjusting the binding profile to match tumor-specific receptor expression patterns, the treatment achieves localized therapeutic action at the tumor site while reducing off-target effects on liver cells.
Solution Approach 2:
The patent converts the potential harm of systemic TNF activation into benefit by using selective receptor coupling to direct the therapeutic effect specifically to tumor cells. The multi-receptor activation capability is harnessed to create a more selective therapeutic window, where the combined receptor engagement produces potent anti-tumor effects while the selective targeting reduces systemic toxicity including liver damage.
Data Source
AI summary
Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.